{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T17:13:37Z","timestamp":1784740417869,"version":"3.55.0"},"reference-count":113,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.intimp.2025.115778","type":"journal-article","created":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T03:45:41Z","timestamp":1762659941000},"page":"115778","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"P1","title":["Fibroblast growth factor 2 in the hotbed of rheumatoid arthritis pathogenesis"],"prefix":"10.1016","volume":"168","author":[{"given":"Gouri H.","family":"Illanad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arulkumaran","family":"Rithvik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahaboobkhan","family":"Rasool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2025.115778_bb0005","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/S0720-048X(98)00038-2","article-title":"The clinical features of rheumatoid arthritis","volume":"27","author":"Grassi","year":"1998","journal-title":"Eur. J. Radiol."},{"key":"10.1016\/j.intimp.2025.115778_bb0010","article-title":"Signaling pathways in rheumatoid arthritis: implications for targeted therapy","volume":"8","author":"Ding","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.intimp.2025.115778_bb0015","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.755844","article-title":"Toward overcoming treatment failure in rheumatoid arthritis","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.115778_bb0020","doi-asserted-by":"crossref","first-page":"5394","DOI":"10.15419\/bmrat.v9i11.779","article-title":"A review of fibroblast-like synoviocytes in the pathogenesis of rheumatoid arthritis: their activation and the inhibition of their apoptosis","volume":"9","author":"Modak","year":"2022","journal-title":"Biomed. Res. Ther."},{"key":"10.1016\/j.intimp.2025.115778_bb0025","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrd2792","article-title":"The FGF family: biology, pathophysiology and therapy","volume":"8","author":"Beenken","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.intimp.2025.115778_bb0030","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.3390\/cells10113242","article-title":"The role of fibroblast growth factor (FGF) Signaling in tissue repair and regeneration","volume":"10","author":"Farooq","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.intimp.2025.115778_bb0035","first-page":"215","article-title":"The fibroblast growth factor signaling pathway, Wiley Interdiscip rev","volume":"4","author":"Ornitz","year":"2015","journal-title":"Dev. Biol."},{"key":"10.1016\/j.intimp.2025.115778_bb0040","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cytogfr.2024.04.001","article-title":"Glycosylation of FGF\/FGFR: an underrated sweet code regulating cellular signaling programs","volume":"77","author":"G\u0119daj","year":"2024","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.intimp.2025.115778_bb0045","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3390\/cimb47040286","article-title":"FGFRL1: structure, molecular function, and involvement in human disease","volume":"47","author":"Guan","year":"2025","journal-title":"Curr. Issues Mol. Biol."},{"key":"10.1016\/j.intimp.2025.115778_bb0050","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.02327","article-title":"Long Pentraxin-3 modulates the angiogenic activity of fibroblast growth Factor-2","volume":"9","author":"Presta","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.115778_bb0055","doi-asserted-by":"crossref","first-page":"28265","DOI":"10.1074\/jbc.M202527200","article-title":"Fibroblast growth factor (FGF)-23 inhibits renal phosphate reabsorption by activation of the mitogen-activated protein kinase pathway","volume":"277","author":"Yamashita","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.intimp.2025.115778_bb0060","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1158\/0008-5472.CAN-09-3033","article-title":"Signal transducers and activators of Transcription-3 binding to the fibroblast growth factor receptor is activated by receptor amplification","volume":"70","author":"Dudka","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2025.115778_bb0065","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.brainresbull.2021.05.017","article-title":"FGF-2 suppresses neuronal autophagy by regulating the PI3K\/Akt pathway in subarachnoid hemorrhage","volume":"173","author":"Wang","year":"2021","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.intimp.2025.115778_bb0070","article-title":"FGF2, an immunomodulatory factor in asthma and chronic obstructive pulmonary disease (COPD), front cell","volume":"8","author":"Tan","year":"2020","journal-title":"Dev. Biol."},{"key":"10.1016\/j.intimp.2025.115778_bb0075","first-page":"339","article-title":"Expression of basic fibroblast growth factor in synovial tissue from patients with rheumatoid arthritis and degenerative joint disease","volume":"73","author":"Qu","year":"1995","journal-title":"Lab. Invest."},{"key":"10.1016\/j.intimp.2025.115778_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110628","article-title":"Pentraxin 3 inhibits fibroblast growth factor 2 induced osteoclastogenesis in rheumatoid arthritis","volume":"131","author":"Zhao","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.intimp.2025.115778_bb0085","doi-asserted-by":"crossref","first-page":"7024","DOI":"10.1038\/s41598-017-07597-8","article-title":"FGF2 cooperates with IL-17 to promote autoimmune inflammation","volume":"7","author":"Shao","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2025.115778_bb0090","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1359\/jbmr.2001.16.11.2074","volume":"16","author":"Chikazu","year":"2001","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.intimp.2025.115778_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2022.113355","article-title":"FGF2 isoforms play distinct roles in tubular epithelial-to-mesenchymal transition in diabetic nephropathy","volume":"420","author":"Luo","year":"2022","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.intimp.2025.115778_bb0100","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3390\/ijms25020849","article-title":"Molecular targeting of the fibroblast growth factor receptor pathway across various cancers","volume":"25","author":"Shan","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2025.115778_bb0105","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jmb.2009.08.007","article-title":"Structural basis of conserved cysteine in the fibroblast growth factor family: evidence for a vestigial half-cystine","volume":"393","author":"Lee","year":"2009","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.intimp.2025.115778_bb0110","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jmb.2008.01.055","article-title":"A logical OR redundancy within the Asx-pro-Asx-Gly type I beta-turn motif","volume":"377","author":"Lee","year":"2008","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.intimp.2025.115778_bb0115","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.cytogfr.2005.01.008","article-title":"Structural basis for fibroblast growth factor receptor activation","volume":"16","author":"Mohammadi","year":"2005","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.intimp.2025.115778_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/950508","article-title":"Alternative splicing of fibroblast growth factor receptor IgIII loops in Cancer","volume":"2012","author":"Holzmann","year":"2012","journal-title":"J. Nucleic Acids"},{"key":"10.1016\/j.intimp.2025.115778_bb0125","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/pro.65","article-title":"The strong dimerization of the transmembrane domain of the fibroblast growth factor receptor (FGFR) is modulated by C-terminal juxtamembrane residues","volume":"18","author":"Peng","year":"2009","journal-title":"Protein Sci."},{"key":"10.1016\/j.intimp.2025.115778_bb0130","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1073\/pnas.70.9.2702","article-title":"Pituitary extracts and steroid hormones in the control of 3T3 cell growth","volume":"70","author":"Armelin","year":"1973","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.intimp.2025.115778_bb0135","doi-asserted-by":"crossref","first-page":"18452","DOI":"10.1016\/S0021-9258(19)81379-0","article-title":"Production, biological activity, and structure of recombinant basic fibroblast growth factor and an analog with cysteine replaced by serine","volume":"263","author":"Fox","year":"1988","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.intimp.2025.115778_bb0140","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1073\/pnas.88.8.3446","article-title":"Three-dimensional structure of human basic fibroblast growth factor, a structural homolog of interleukin 1 beta","volume":"88","author":"Zhang","year":"1991","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.intimp.2025.115778_bb0145","doi-asserted-by":"crossref","first-page":"508","DOI":"10.3390\/pharmaceutics12060508","article-title":"Fibroblast growth factor 2\u2014a review of stabilisation approaches for clinical applications","volume":"12","author":"Benington","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.intimp.2025.115778_bb0150","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S0014-5793(00)01189-3","article-title":"The high molecular weight isoforms of basic fibroblast growth factor (FGF-2): an insight into an intracrine mechanism","volume":"468","author":"Delrieu","year":"2000","journal-title":"FEBS Lett."},{"key":"10.1016\/j.intimp.2025.115778_bb0155","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.28985","article-title":"Key steps in unconventional secretion of fibroblast growth factor 2 reconstituted with purified components","volume":"6","author":"Steringer","year":"2017","journal-title":"Elife"},{"key":"10.1016\/j.intimp.2025.115778_bb0160","doi-asserted-by":"crossref","first-page":"27015","DOI":"10.1074\/jbc.R115.689257","article-title":"The startling properties of fibroblast growth factor 2: how to exit mammalian cells without a signal peptide at hand","volume":"290","author":"La Venuta","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.intimp.2025.115778_bb0165","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.3390\/biom14121622","article-title":"Decoding FGF\/FGFR Signaling: insights into biological functions and disease relevance","volume":"14","author":"Edirisinghe","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.intimp.2025.115778_bb0170","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.chembiol.2005.05.013","article-title":"Chemical approaches to define the structure-activity relationship of heparin-like glycosaminoglycans","volume":"12","author":"Noti","year":"2005","journal-title":"Chem. Biol."},{"key":"10.1016\/j.intimp.2025.115778_bb0175","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.778752","article-title":"Heparan Sulfate biosynthesis and sulfation profiles as modulators of Cancer signalling and progression","volume":"11","author":"Marques","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.intimp.2025.115778_bb0180","doi-asserted-by":"crossref","first-page":"a004952","DOI":"10.1101\/cshperspect.a004952","article-title":"Heparan Sulfate proteoglycans","volume":"3","author":"Sarrazin","year":"2011","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.intimp.2025.115778_bb0185","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41392-020-00222-7","article-title":"FGF\/FGFR signaling in health and disease","volume":"5","author":"Xie","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.intimp.2025.115778_bb0190","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1007\/s10439-019-02202-7","article-title":"Fibroblast growth Factor-2 binding to heparan Sulfate proteoglycans varies with shear stress in flow-adapted cells","volume":"47","author":"Garcia","year":"2019","journal-title":"Ann. Biomed. Eng."},{"key":"10.1016\/j.intimp.2025.115778_bb0195","doi-asserted-by":"crossref","first-page":"C896","DOI":"10.1152\/ajpcell.00050.2022","article-title":"Coreceptor functions of cell surface heparan sulfate proteoglycans","volume":"322","author":"Hayashida","year":"2022","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.intimp.2025.115778_bb0200","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.celrep.2014.12.043","article-title":"Heparan Sulfate proteoglycans regulate Fgf Signaling and cell polarity during collective cell migration","volume":"10","author":"Venero Galanternik","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/j.intimp.2025.115778_bb0205","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.3390\/molecules25184215","article-title":"Heparan Sulfate proteoglycans biosynthesis and post synthesis mechanisms combine few enzymes and few Core proteins to generate extensive structural and functional diversity","volume":"25","author":"Annaval","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.intimp.2025.115778_bb0210","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/36285","article-title":"Mutation of the mouse klotho gene leads to a syndrome resembling ageing","volume":"390","author":"Kuro-o","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2025.115778_bb0215","article-title":"Pathobiology of the klotho antiaging protein and therapeutic considerations, Frontiers","volume":"3","author":"Prud\u2019homme","year":"2022","journal-title":"Aging"},{"key":"10.1016\/j.intimp.2025.115778_bb0220","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.bbagen.2009.02.005","article-title":"Klotho and aging","volume":"1790","author":"Kuro-o","year":"2009","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"10.1016\/j.intimp.2025.115778_bb0225","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.3390\/cells10092418","article-title":"The Saga of endocrine FGFs","volume":"10","author":"Phan","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.intimp.2025.115778_bb0230","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1146\/annurev-physiol-030212-183727","article-title":"Fibroblast growth factor 23 and klotho: physiology and pathophysiology of an endocrine network of mineral metabolism","volume":"75","author":"Hu","year":"2013","journal-title":"Annu. Rev. Physiol."},{"key":"10.1016\/j.intimp.2025.115778_bb0235","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1172\/JCI31330","article-title":"A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis","volume":"117","author":"Ichikawa","year":"2007","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.intimp.2025.115778_bb0240","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1681\/ASN.2015111266","article-title":"Chronic hyperphosphatemia and vascular calcification are reduced by stable delivery of soluble klotho","volume":"28","author":"Hum","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.intimp.2025.115778_bb0245","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1210\/er.2013-1079","article-title":"Molecular basis of klotho: from gene to function in aging","volume":"36","author":"Xu","year":"2015","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.intimp.2025.115778_bb0250","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.bone.2013.09.024","article-title":"FGF2 stimulates osteogenic differentiation through ERK induced TAZ expression","volume":"58","author":"Byun","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.intimp.2025.115778_bb0255","doi-asserted-by":"crossref","first-page":"3283","DOI":"10.1002\/tox.24180","article-title":"<scp>FGF23<\/scp> facilitates <scp>IL<\/scp> \u22121\u03b2 synthesis in rheumatoid arthritis through activating <scp>PI3K<\/scp>, Akt, and <scp>NF-\u03baB<\/scp> pathways","volume":"39","author":"Hu","year":"2024","journal-title":"Environ. Toxicol."},{"key":"10.1016\/j.intimp.2025.115778_bb0260","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1390453","article-title":"Fibroblast growth factor signaling in macrophage polarization: impact on health and diseases","volume":"15","author":"Shen","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.115778_bb0265","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1084\/jem.20081859","article-title":"Critical role of phospholipase C\u03b32 in integrin and fc receptor-mediated neutrophil functions and the effector phase of autoimmune arthritis","volume":"206","author":"Jakus","year":"2009","journal-title":"Journal of Experimental Medicine"},{"key":"10.1016\/j.intimp.2025.115778_bb0270","first-page":"166665","article-title":"FGFR2 upregulates PAI-1 via JAK2\/STAT3 signaling to induce M2 polarization of macrophages in colorectal cancer","volume":"2023","author":"Li","year":"1869","journal-title":"Biochim. Biophys. Acta (BBA) - Mol. Basis Dis."},{"key":"10.1016\/j.intimp.2025.115778_bb0275","doi-asserted-by":"crossref","first-page":"15433","DOI":"10.1038\/ncomms15433","article-title":"Non-cell-autonomous activation of IL-6\/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis","volume":"8","author":"Zhou","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2025.115778_bb0280","first-page":"603","article-title":"Angiogenesis in rheumatoid arthritis: pathological characterization, pathogenic mechanisms, and nano-targeted therapeutic strategies","volume":"50","author":"Zhao","year":"2025","journal-title":"Bioact Mater"},{"key":"10.1016\/j.intimp.2025.115778_bb0285","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1182\/blood-2004-04-1358","article-title":"Stimulation of endothelial cell proliferation by FGF-2 in the presence of fibrinogen requires alphavbeta3","volume":"104","author":"Sahni","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2025.115778_bb0290","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1242\/jcs.02483","article-title":"VEGF-A and FGF-2 synergistically promote neoangiogenesis through enhancement of endogenous PDGF-B-PDGFRbeta signaling","volume":"118","author":"Kano","year":"2005","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.intimp.2025.115778_bb0295","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13018-021-02887-4","article-title":"miR-653-5p suppresses the viability and migration of fibroblast-like synoviocytes by targeting FGF2 and inactivation of the Wnt\/beta-catenin pathway","volume":"17","author":"Dong","year":"2022","journal-title":"J. Orthop. Surg. Res."},{"key":"10.1016\/j.intimp.2025.115778_bb0300","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1167\/iovs.11-9102","article-title":"NF-\u03baB is the transcription factor for FGF-2 that causes endothelial mesenchymal transformation in cornea","volume":"53","author":"Lee","year":"2012","journal-title":"Investigative Opthalmology & Visual Science"},{"key":"10.1016\/j.intimp.2025.115778_bb0305","doi-asserted-by":"crossref","first-page":"450","DOI":"10.4049\/jimmunol.168.1.450","article-title":"Fibroblast growth Factor-2 determines severity of joint disease in adjuvant-induced arthritis in rats","volume":"168","author":"Yamashita","year":"2002","journal-title":"The Journal of Immunology"},{"key":"10.1016\/j.intimp.2025.115778_bb0310","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1093\/rheumatology\/38.8.714","article-title":"Involvement of fibroblast growth factor-2 in joint destruction of rheumatoid arthritis patients","volume":"38","author":"Manabe","year":"1999","journal-title":"Rheumatology"},{"key":"10.1016\/j.intimp.2025.115778_bb0315","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1101\/gad.266551.115","article-title":"Fibroblast growth factor signaling in skeletal development and disease","volume":"29","author":"Ornitz","year":"2015","journal-title":"Genes Dev."},{"key":"10.1016\/j.intimp.2025.115778_bb0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2022.109348","article-title":"FGF2 positively regulates osteoclastogenesis via activating the ERK-CREB pathway","volume":"727","author":"Wen","year":"2022","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.intimp.2025.115778_bb0325","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.cytogfr.2017.09.003","article-title":"Fibroblast growth factor 2 as an antifibrotic: antagonism of myofibroblast differentiation and suppression of pro-fibrotic gene expression","volume":"38","author":"Dolivo","year":"2017","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.intimp.2025.115778_bb0330","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1002\/2211-5463.13691","article-title":"Fibroblast growth factor 2 acts as an upstream regulator of inhibition of pulmonary fibroblast activation","volume":"13","author":"Tian","year":"2023","journal-title":"FEBS Open Bio"},{"key":"10.1016\/j.intimp.2025.115778_bb0335","doi-asserted-by":"crossref","first-page":"16006","DOI":"10.1038\/s41598-022-20036-7","article-title":"FGF-2 enhances fibrogenetic changes in TGF-\u03b22 treated human conjunctival fibroblasts","volume":"12","author":"Tsugeno","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2025.115778_bb0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.122115","article-title":"Unleashing the pathological imprinting of cancer in autoimmunity: is ZEB1 the answer?","volume":"332","author":"Rithvik","year":"2023","journal-title":"Life Sci."},{"key":"10.1016\/j.intimp.2025.115778_bb0345","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1074\/jbc.RA117.000295","article-title":"Fibroblast growth factor 2 induces proliferation and fibrosis via SNAI1-mediated activation of CDK2 and ZEB1 in corneal endothelium","volume":"293","author":"Lee","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.intimp.2025.115778_bb0350","doi-asserted-by":"crossref","first-page":"4943","DOI":"10.4049\/jimmunol.1501503","article-title":"Cytosolic low molecular weight FGF2 orchestrates RIG-I-mediated innate immune response","volume":"195","author":"Liu","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2025.115778_bb0355","doi-asserted-by":"crossref","first-page":"4908","DOI":"10.1038\/s41467-025-60092-x","article-title":"Soft matrix promotes immunosuppression in tumor-resident immune cells via COX-FGF2 signaling","volume":"16","author":"Peura","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2025.115778_bb0360","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1038\/s41467-020-17914-x","article-title":"FGF2 alters macrophage polarization, tumour immunity and growth and can be targeted during radiotherapy","volume":"11","author":"Im","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2025.115778_bb0365","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s43556-024-00203-0","article-title":"Deleting fibroblast growth factor 2 in macrophages aggravates septic acute lung injury by increasing M1 polarization and inflammatory cytokine secretion","volume":"5","author":"Yi","year":"2024","journal-title":"Molecular Biomedicine"},{"key":"10.1016\/j.intimp.2025.115778_bb0370","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0209733","article-title":"Application of CNTF or FGF-2 increases the number of M2-like macrophages after optic nerve injury in adult Rana pipiens","volume":"14","author":"Blanco","year":"2019","journal-title":"PloS One"},{"key":"10.1016\/j.intimp.2025.115778_bb0375","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1093\/rheumatology\/kead220","article-title":"Fibroblast growth factor receptor 1 as a potential marker of terminal effector peripheral T helper cells in rheumatoid arthritis patients","volume":"62","author":"Etori","year":"2023","journal-title":"Rheumatology"},{"key":"10.1016\/j.intimp.2025.115778_bb0380","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1172\/JCI17100","article-title":"A mutation in a CD44 variant of inflammatory cells enhances the mitogenic interaction of FGF with its receptor","volume":"111","author":"Nedvetzki","year":"2003","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.intimp.2025.115778_bb0385","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/s41467-017-00452-4","article-title":"Tumor-associated B-cells induce tumor heterogeneity and therapy resistance","volume":"8","author":"Somasundaram","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2025.115778_bb0390","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1167\/iovs.66.1.58","article-title":"ENO2-regulated glycolysis in endothelial cells contributes to FGF2-induced retinal neovascularization","volume":"66","author":"Liao","year":"2025","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.intimp.2025.115778_bb0395","doi-asserted-by":"crossref","first-page":"612","DOI":"10.3390\/nano10040612","article-title":"Internalized FGF-2-loaded nanoparticles increase nuclear ERK1\/2 content and result in lung Cancer cell death","volume":"10","author":"Miao","year":"2020","journal-title":"Nanomaterials"},{"key":"10.1016\/j.intimp.2025.115778_bb0400","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s11010-021-04287-y","article-title":"Lactic acid induces fibroblast growth factor 23 (FGF23) production in UMR106 osteoblast-like cells","volume":"477","author":"Alber","year":"2022","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.intimp.2025.115778_bb0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcp.2020.101538","article-title":"Fibroblast growth factor-2 ameliorates tumor necrosis factor-alpha-induced osteogenic damage of human bone mesenchymal stem cells by improving oxidative phosphorylation","volume":"52","author":"Hao","year":"2020","journal-title":"Mol. Cell. Probes"},{"key":"10.1016\/j.intimp.2025.115778_bb0410","doi-asserted-by":"crossref","first-page":"14026","DOI":"10.1111\/jcmm.16013","article-title":"Metabolic reprogramming of glycolysis and glutamine metabolism are key events in myofibroblast transition in systemic sclerosis pathogenesis","volume":"24","author":"Henderson","year":"2020","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.intimp.2025.115778_bb0415","doi-asserted-by":"crossref","DOI":"10.3390\/cells10102735","article-title":"A cardiac mitochondrial FGFR1 mediates the antithetical effects of FGF2 isoforms on permeability transition","volume":"10","author":"Srisakuldee","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.intimp.2025.115778_bb0420","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41392-024-01954-6","article-title":"Metabolic regulation of the immune system in health and diseases: mechanisms and interventions","volume":"9","author":"Hu","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.intimp.2025.115778_bb0425","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1084\/jem.20110278","article-title":"HIF1\u03b1\u2013dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells","volume":"208","author":"Shi","year":"2011","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.intimp.2025.115778_bb0430","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/s41423-024-01148-8","article-title":"Cellular metabolism regulates the differentiation and function of T-cell subsets","volume":"21","author":"Ma","year":"2024","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.intimp.2025.115778_bb0435","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/art.42674","article-title":"Role and Therapeutic Potential for Targeting Fibroblast Growth Factor 10\/ <scp>FGFR1<\/scp> in Relapsed Rheumatoid Arthritis","volume":"76","author":"Meng","year":"2024","journal-title":"Arthritis & Rheumatology"},{"key":"10.1016\/j.intimp.2025.115778_bb0440","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1038\/bjc.2013.550","article-title":"The FGFR1 inhibitor PD173074 induces mesenchymal\u2013epithelial transition through the transcription factor AP-1","volume":"109","author":"Nguyen","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.intimp.2025.115778_bb0445","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.3390\/cancers15092528","article-title":"Targeting FGFRs using PD173074 as a novel therapeutic strategy in cholangiocarcinoma","volume":"15","author":"Balasubramanian","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.intimp.2025.115778_bb0450","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ccr.2013.02.018","article-title":"Molecular mechanism of SSR128129E, an extracellularly acting, small-molecule, allosteric inhibitor of FGF receptor Signaling","volume":"23","author":"Herbert","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.intimp.2025.115778_bb0455","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ejca.2016.03.068","article-title":"Targeting FGFR2 with alofanib (RPT835) shows potent activity in tumour models","volume":"61","author":"Tsimafeyeu","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.intimp.2025.115778_bb0460","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2021.1981202","article-title":"Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer","volume":"13","author":"Xiang","year":"2021","journal-title":"MAbs"},{"key":"10.1016\/j.intimp.2025.115778_bb0465","series-title":"Gene Therapy Targeting Sustained FGF23-ERK Signaling Alleviates Kidney Inflammation","author":"Salas-Bastos","year":"2024"},{"key":"10.1016\/j.intimp.2025.115778_bb0470","series-title":"A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid\/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)","year":"2025"},{"key":"10.1016\/j.intimp.2025.115778_bb0475","series-title":"An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer","year":"2025"},{"key":"10.1016\/j.intimp.2025.115778_bb0480","series-title":"Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma (FIERCE-21)","author":"Escalation","year":"2025"},{"key":"10.1016\/j.intimp.2025.115778_bb0485","series-title":"A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric\/Gastroesophageal Junction Cancer (FIGHT)","year":"2025"},{"key":"10.1016\/j.intimp.2025.115778_bb0490","series-title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","year":"2025"},{"key":"10.1016\/j.intimp.2025.115778_bb0495","series-title":"Phase 2 Study of HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma","year":"2025"},{"key":"10.1016\/j.intimp.2025.115778_bb0500","series-title":"Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma (FORT-1)","year":"2025"},{"key":"10.1016\/j.intimp.2025.115778_bb0505","series-title":"FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression","year":"2025"},{"key":"10.1016\/j.intimp.2025.115778_bb0510","series-title":"Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma","year":"2025"},{"key":"10.1016\/j.intimp.2025.115778_bb0515","series-title":"Patients with ICC and Other Advanced Solid Tumors","article-title":"A first-in-human study of highly selective FGFR2 inhibitor, RLY-4008","author":"REFOCUS","year":"2025"},{"key":"10.1016\/j.intimp.2025.115778_bb0520","series-title":"Study of Alofanib in Patients With Metastatic Gastric Cancer","year":"2025"},{"key":"10.1016\/j.intimp.2025.115778_bb0525","series-title":"Fulvestrant, Palbociclib and Erdafitinib in ER+\/HER2\u2212\/FGFR-amplified Metastatic Breast Cancer","year":"2025"},{"key":"10.1016\/j.intimp.2025.115778_bb0530","series-title":"HMPL-453 (FGFR Inhibitor) in Combination With Chemotherapy or Anti-PD-1 Antibody in Advanced Solid Tumors","year":"2025"},{"key":"10.1016\/j.intimp.2025.115778_bb0535","series-title":"Phase 1b\/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma (FORT-2)","year":"2025"},{"key":"10.1016\/j.intimp.2025.115778_bb0540","doi-asserted-by":"crossref","first-page":"4034","DOI":"10.3390\/cancers15164034","article-title":"Preclinical evaluation of the FGFR-family inhibitor Futibatinib for Pediatric rhabdomyosarcoma","volume":"15","author":"Wu","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.intimp.2025.115778_bb0545","doi-asserted-by":"crossref","DOI":"10.2174\/0118761429261684231002062505","article-title":"Targeting FGFR3 is a useful therapeutic strategy for rheumatoid arthritis treatment","volume":"17","author":"Yu","year":"2023","journal-title":"Curr. Mol. Pharmacol."},{"key":"10.1016\/j.intimp.2025.115778_bb0550","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/art.42674","article-title":"Role and Therapeutic Potential for Targeting Fibroblast Growth Factor 10\/ <scp>FGFR1<\/scp> in Relapsed Rheumatoid Arthritis","volume":"76","author":"Meng","year":"2024","journal-title":"Arthritis & Rheumatology"},{"key":"10.1016\/j.intimp.2025.115778_bb0555","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1093\/rheumatology\/38.8.714","article-title":"Involvement of fibroblast growth factor-2 in joint destruction of rheumatoid arthritis patients","volume":"38","author":"Manabe","year":"1999","journal-title":"Rheumatology"},{"key":"10.1016\/j.intimp.2025.115778_bb0560","doi-asserted-by":"crossref","first-page":"450","DOI":"10.4049\/jimmunol.168.1.450","article-title":"Fibroblast growth Factor-2 determines severity of joint disease in adjuvant-induced arthritis in rats","volume":"168","author":"Yamashita","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2025.115778_bb0565","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00011-025-02012-9","article-title":"Roquin-1 interaction with Regnase-1 inhibits the progression of rheumatoid arthritis via suppressing FGF2 expression and NF-\u03baB pathway","volume":"74","author":"Wang","year":"2025","journal-title":"Inflamm. Res."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925017667?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925017667?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T19:36:35Z","timestamp":1781897795000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576925017667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":113,"alternative-id":["S1567576925017667"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115778","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fibroblast growth factor 2 in the hotbed of rheumatoid arthritis pathogenesis","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115778","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115778"}}